docetaxel anhydrous has been researched along with losartan potassium in 11 studies
| Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) | Studies (losartan potassium) | Trials (losartan potassium) | Recent Studies (post-2010) (losartan potassium) |
|---|---|---|---|---|---|
| 12,110 | 3,216 | 6,920 | 24,390 | 2,493 | 5,408 |
| Protein | Taxonomy | docetaxel anhydrous (IC50) | losartan potassium (IC50) |
|---|---|---|---|
| Bile salt export pump | Homo sapiens (human) | 8.53 | |
| Type-1A angiotensin II receptor | Rattus norvegicus (Norway rat) | 0.0082 | |
| Type-1B angiotensin II receptor | Rattus norvegicus (Norway rat) | 0.0049 | |
| Type-2 angiotensin II receptor | Rattus norvegicus (Norway rat) | 0.0082 | |
| 5-hydroxytryptamine receptor 1A | Mus musculus (house mouse) | 0.0082 | |
| Type-1 angiotensin II receptor | Cavia porcellus (domestic guinea pig) | 0.018 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (72.73) | 29.6817 |
| 2010's | 3 (27.27) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Colowick, AB; Fleishman, A; Glaspy, JA; Jadeja, JS; Justice, G; Rossi, G | 1 |
| Depisch, D; Hejna, M; Kornek, GV; Lang, F; Lenauer, A; Raderer, M; Scheithauer, W; Schmid, K; Schüll, B | 1 |
| Domchek, SM; Fox, K; Hwang, WT; Schwartz, J | 1 |
| Hahn, M; Lauschner, I; Rudlowski, C; Schneeweiss, A; Schuetz, F; Sinn, HP; Sohn, C; von Fournier, D | 1 |
| Burkey, BB; Chen, C; Cmelak, AJ; Kane, MA; Kish, B; Murphy, BA; Netterville, JL; Raben, D; Shakhtour, B; Shyr, Y; Song, JI; Willey, CD | 1 |
| Chaigneau, L; Demarchi, M; Lorgis, V; Maurina, T; Meaux-Ruault, N; N'guyen, T; Pivot, X; Stein, U; Thiery-Vuillemin, A; Villanueva, C | 1 |
| Ba-Ssalamah, A; Brodowicz, T; Hejna, M; Pluschnig, U; Püspök, A; Raderer, M; Schmidinger, M; Zacherl, J; Zielinski, CC | 1 |
| Bolger, M; Dunphy, F; Edelman, MJ; Green, MR; Gu, L; Hoffman, P; Khatri, J; Miller, AA; Vokes, EE; Wang, XF | 1 |
| Bello, E; Bianchi, R; Camozzi, F; Canta, A; Cavaletti, G; Cervellini, I; D'incalci, M; Frapolli, R; Ghezzi, P; Lauria, G; Lombardi, R; Melcangi, RC; Oggioni, N; Porretta-Serapiglia, C; Roglio, I | 1 |
| Cavaletti, G; Chiorazzi, A; Maggioni, D; Meregalli, C; Nicolini, G; Tredici, G | 1 |
6 trial(s) available for docetaxel anhydrous and losartan potassium
| Article | Year |
|---|---|
A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant disease.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Darbepoetin alfa; Deoxycytidine; Docetaxel; Erythropoietin; Fatigue; Female; Gemcitabine; Humans; Injections, Subcutaneous; Male; Middle Aged; Neoplasms; Paclitaxel; Pilot Projects; Taxoids; Treatment Outcome | 2003 |
Effective combination chemotherapy with bimonthly docetaxel and cisplatin with or without hematopoietic growth factor support in patients with advanced gastroesophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Therapy, Combination; Erythropoietin; Esophageal Neoplasms; Esophagogastric Junction; Female; Granulocyte Colony-Stimulating Factor; Humans; Male; Maximum Tolerated Dose; Middle Aged; Stomach Neoplasms; Survival Rate; Taxoids; Treatment Outcome | 2003 |
Dose-dense primary systemic chemotherapy with gemcitabine plus epirubicin sequentially followed by docetaxel for early breast cancer: final results of a phase I/II trial.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Darbepoetin alfa; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Erythropoietin; Female; Filgrastim; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Ki-67 Antigen; Middle Aged; Neutropenia; Polyethylene Glycols; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Recombinant Proteins; Taxoids; Treatment Outcome | 2005 |
A Phase II multi-institutional trial of chemoradiation using weekly docetaxel and erythropoietin for high-risk postoperative head and neck cancer patients.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Dose Fractionation, Radiation; Erythropoietin; Female; Head and Neck Neoplasms; Hemoglobin A; Humans; Male; Middle Aged; Mouth Mucosa; Prospective Studies; Radiation Injuries; Radiation-Sensitizing Agents; Radiotherapy Dosage; Stomatitis; Taxoids | 2007 |
Phase II study of docetaxel in combination with oxaliplatin in patients with metastatic or locally advanced esophagogastric cancer previously untreated with chemotherapy for advanced disease: results of the Central European Cooperative Oncology Group Stud
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Erythropoietin; Esophageal Neoplasms; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Injections, Subcutaneous; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Survival Rate; Taxoids | 2008 |
Phase II randomized study of dose-dense docetaxel and cisplatin every 2 weeks with pegfilgrastim and darbepoetin alfa with and without the chemoprotector BNP7787 in patients with advanced non-small cell lung cancer (CALGB 30303).
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Darbepoetin alfa; Docetaxel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Erythropoietin; Feasibility Studies; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematinics; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Mesna; Middle Aged; Neoplasm Staging; Neutropenia; Polyethylene Glycols; Prognosis; Recombinant Proteins; Survival Rate; Taxoids | 2008 |
5 other study(ies) available for docetaxel anhydrous and losartan potassium
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Evaluation of anemia, neutropenia and skin toxicities in standard or dose-dense doxorubicin/cyclophosphamide (AC)-paclitaxel or docetaxel adjuvant chemotherapy in breast cancer.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Erythropoietin; Female; Humans; Incidence; Middle Aged; Neutropenia; Paclitaxel; Retrospective Studies; Skin Diseases; Taxoids | 2005 |
Anticancer therapy in patients with porphyrias: evidence today.
Topics: Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Docetaxel; Epoetin Alfa; Erythropoietin; Female; Granulocyte Colony-Stimulating Factor; Hematinics; Humans; Letrozole; Middle Aged; Nitriles; Porphyria, Acute Intermittent; Porphyria, Variegate; Recombinant Proteins; Risk Assessment; Taxoids; Triazoles; Uterine Neoplasms | 2008 |
The neuroprotective effect of erythropoietin in docetaxel-induced peripheral neuropathy causes no reduction of antitumor activity in 13762 adenocarcinoma-bearing rats.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Docetaxel; Drug Interactions; Erythropoietin; Female; Humans; Neuroprotective Agents; Peripheral Nervous System Diseases; Rats; Rats, Inbred F344; Taxoids; Xenograft Model Antitumor Assays | 2010 |
Different effects of erythropoietin in cisplatin- and docetaxel-induced neurotoxicity: an in vitro study.
Topics: Animals; Antineoplastic Agents; Cells, Cultured; Cisplatin; Docetaxel; Erythropoietin; Ganglia, Spinal; Nerve Degeneration; Neuroprotective Agents; Peripheral Nervous System Diseases; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Sensory Receptor Cells; Signal Transduction; Taxoids | 2010 |